Using real world data to experience real world success 2

Leveraging data analysis to successfully launch a chronic cough drug

Assessing drug performance on health outcomes, utilization and total costs of care associated with the drug is critical not only for pharmaceutical companies but also payers to ensure value-based outcomes. Data-driven insights become especially important as life sciences companies enter value-based contracts with payers. Performing such analysis needs a strong foundation of data assets, clinical and analytics expertise to truly perform healthcare economics outcomes research validation. With this intelligence, pharmaceutical companies can place less financial burden on patients, while entering more favorable contracts with payers.

EXL’s solution

EXL’s Health Economics and Outcomes Research (HEOR) solution can help meet the challenges associated with proving optimal health outcomes as well as financial success. EXL’s HEOR solution not only brings this valuable real-world data to the table, but it also empowers payers to help life sciences companies effectively leverage this information to improve outcomes and reduce costs by offering.

Perhaps most importantly, EXL works closely with life sciences companies to implement a standardized, proven approach that is highly likely to improve outcomes and costs.

Case study:

Leveraging data analysis to successfully launch a chronic cough drug

Assessing challenges

The organization wanted to analyze potential health outcomes and cost of care for a chronic cough drug that was still in clinical trials. Doing so would go a long way in improving public health. As such, the company wanted to differentiate patients by exploring various attributes that set them apart such as:

  • Where they live
  • Types of prescribed medications they take
  • Other conditions or co-morbidities they suffer from
  • Their smoking status

To accomplish this, the company needed to arrive at a 360-degree view of patients and their affiliated healthcare providers. With this analysis, they could understand patient impactability scores that identify atrisk patients for whom care management interventions (i.e., care programs, patient education, nutrition consulting, digital messaging, etc.) are most likely to succeed.

The company simply did not have access to substantial, meaningful data on these various patient populations. EXL’s HEOR solution not only provided access to this data but also worked closely with the pharmaceutical company to develop criteria that would parse out the patients who were actually experiencing “chronic cough.” Once a patient universe had been defined, additional clinical business rules were used to further “fine-tune” the patient populations that have a high probability of suffering from chronic cough. In fact, EXL segmented chronic cough patients under Medicare Advantage coverage, which represents 71% of the entire chronic cough study population, into seven personas by leveraging a proprietary clustering algorithm that takes members’ social-economic characteristics including but not limited to household income, education, and employment into consideration.

Taking action

The company leveraged patient centric advanced analytics to help identify patient trends, specifically utilizing patient centric cost of care scores to help inform market access and prior authorization (PA) strategies, and to better understand patient personas both nationally and regionally. With this more sophisticated understanding of patient impactability scores, the company could better identify at-risk patients for whom care management interventions (i.e. care programs, patient education, nutrition consulting, digital messaging, etc.) are most likely to be successful.

In addition, the life sciences company could use the analysis to better develop targeted marketing programs for the chronic cough drug as soon as it received regulatory approval. What’s more, the life sciences company could rely on this information to better promote its therapy to healthcare providers who work in geographic locations where a large number of chronic cough patients reside.